Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme
This integer risk score for new-onset hyperkalaemia in patients with chronic kidney disease and Type 2 diabetes could facilitate tailored treatment strategies and mitigate hyperkalaemia in high-risk patients.
Authors
- Marc Lambelet
- Gerasimos S Filippatos (ORCID: https://orcid.org/0000-0002-5640-0332)
- Andrea Horvat-Broecker
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- Katja Rohwedder
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Youssef Farag (ORCID: https://orcid.org/0000-0003-0106-8456)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Biff F. Palmer (ORCID: https://orcid.org/0000-0002-7322-4692)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- João Pedro Ferreira (ORCID: https://orcid.org/0000-0002-2304-6138)
- Bertram Pitt
- Stefan D. Anker
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Bayer (United States) (US)
- Inserm (FR)
- National and Kapodistrian University of Athens (GR)
- University of Würzburg (DE)
- University of Michigan (US)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario 12 De Octubre (ES)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- German Centre for Cardiovascular Research (DE)
- French Clinical Research Infrastructure Network (FR)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- The University of Texas Southwestern Medical Center (US)
- Université de Lorraine (FR)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1093/eurheartj/ehaf258
- Citations
- 8
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Bayer